Has saving lives become an afterthought for the US healthcare industry?
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.
“Let’s not fold to advocacy pressure in 2014,” Kevin Young, Gilead’s executive vice president for commercial operations, wrote in an internal email. ‘‘Let’s hold our position whatever competitors do or whatever the headlines.”
If you believe that placing huge profits ahead of saving lives is just plain wrong, click HERE to read about Bernie Sanders’ plan to lower the cost of soaring drug prices.